Shanghai Journal of Stomatology ›› 2016, Vol. 25 ›› Issue (6): 729-733.

Previous Articles     Next Articles

Expressions and clinical significance of TGF-βRⅡ and NF-κB in oral squamous cell carcinoma

JIANG Li-Lan, ZHAO Ya-Jun, LI Yong   

  1. Department of Oral and Maxillofacial Surgery, the Affiliated Hospital of Stomatology, Chongqing Medical University; Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences; Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education. Chongqing 401147, China
  • Received:2016-06-13 Online:2016-12-25 Published:2016-12-29

Abstract: PURPOSE: To investigate the expression of nuclear factor κappa-B (NF-κB) and transforming growth factor β receptor Ⅱ (TGF-βRⅡ) and their clinical pathological significance in oral squamous cell carcinoma(OSCC). METHODS: The expression of NF-κB and TGF-βRⅡ in 60 OSCC samples, 20 adjacent tissues, 29 metastatic lymph nodes and 10 non-metastatic lymph nodes were detected by immunohistological method. Statistical analysis was performed with SPSS 20.0 software package. RESULTS: The expression of NF-κB in OSCC and metastatic lymph nodes was significantly higher than that in the adjacent tissues and non-metastatic lymph nodes, respectively (P<0.05). However, the expression of TGF-βRⅡ in OSCC and metastatic lymph nodes was significantly lower than that in the adjacent tissues and non-metastatic lymph nodes, respectively (P<0.05). NF-κB was negatively correlated with TGF-βRⅡ. The expression of NF-κB in patients with lower differentiation, lymphatic metastasis and higher grade were significantly higher than in patients with higher differentiation, lower grade and without lymphatic metastasis (P<0.05), respectively. NF-κB was a predicator of OSCC. CONCLUSIONS: NF-κB is negatively correlated with TGF-βRⅡ.NF-κB and TGF-βRⅡ are associated with the progression of OSCC. NF-κB may promote angiogenesis through down-regulating the expression of TGF-βRⅡ, which promotes progression of OSCC.

Key words: Oral squamous cell carcinoma, NF-κ, B, TGF-β, RⅡ, Tumor metastasis

CLC Number: